Answers are grounded in this paper and cite their sources.
Background. Metabolic dysfunction-associated steatotic liver disease (MASLD) is a leading cause of chronic liver injury, and both excess adiposity and dysglycaemia have been implicated in its progression. However, the association between fasting plasma glucose and ALT after accounting for adiposity remains insufficiently characterised in adults aged 45–65 years presenting with elevated ALT. Methods. We conducted a cross-sectional study of 511 adults aged 45–65 years with elevated serum alanine aminotransferase (ALT) attending a metabolic liver clinic. Participants were stratified by fasting plasma glucose (FPG) into four groups: normal (< 5.6 mmol/L), impaired fasting glucose (5.6 to < 7.0), diabetic range (7.0 to < 10.0) and markedly elevated (≥ 10.0). The primary outcome was ALT analysed as log-transformed continuous values; secondary outcomes were marked ALT elevation (ALT ≥ 3× upper limit of normal [ULN]) and elevated FIB-4 (≥ 2.67). Multivariable linear and logistic regression adjusted for sex, age, body mass index (BMI), waist circumference, triglycerides, total cholesterol and uric acid. Exploratory liver transcriptomic analyses of glycolysis, insulin-signalling and lactylation-related gene sets were performed in three public cohorts. Results. Higher fasting glucose was associated with higher ALT levels in a graded manner. After adjustment, ALT was 1.28-fold (95% CI 1.07–1.52), 1.66-fold (1.36–2.02) and 2.68-fold (2.06–3.47) higher in the impaired-fasting-glucose, diabetic-range and markedly-elevated groups than in the normal group; each 1 mmol/L increment in fasting glucose was associated with a 9.0% increase in ALT (geometric mean ratio 1.09, 95% CI 1.06–1.12; P = 2.4×10⁻¹⁰). The association persisted in participants with imaging-confirmed steatosis (GMR 1.089), and a parallel analysis using HbA1c gave a similar estimate (13.5% higher ALT per 1-percentage-point increment; P = 9.5×10⁻¹¹). The association was directionally consistent across subgroups, although effect size differed across some strata. Glycaemic control was poor: only 3.3% of participants with diabetes had fasting glucose below 7.0 mmol/L. Exploratory liver transcriptomic analyses identified glycolysis- and lactylation-related signatures associated with serum ALT; no statistically significant association of module scores with fasting glucose or HOMA-IR was detected. These transcriptomic findings are hypothesis-generating. Conclusions. Among adults aged 45–65 years referred for elevated ALT, higher fasting plasma glucose was associated with higher ALT levels after adjustment for measured adiposity and other metabolic factors, and glycaemic control was markedly suboptimal in this population (median HbA1c 9.4% among participants with previously diagnosed diabetes). Exploratory liver transcriptomic analyses identified related metabolic signatures associated with hepatic injury. These cross-sectional findings do not establish causality and warrant longitudinal validation.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: